| Trusopt (U.S.N.L.M.) | |
|---|---|
| Dosing | 1 drop tid (monotherapy) bid (additive therapy) |
| Chem Specs | dorzolamide 2.0% |
| Quantities | 5, 10ml |
| Cost | 18.00/5ml |
| Class | carbonic anhydrase inhibitor |
| Action | Inhibition of carbonic anhydrase II in the ciliary processes presumably slows the formation of bicarbonate with subsequent reduction in sodium and fluid transport. |
| Usage | Indicated for elevated IOP of ocular hypertension or open-angle glaucoma. |
| Dorzolamide is a sulfonamide but one retrospective study1 suggested that topical CIA's can be safely used despite a patient reported history of "sulfa alergy". Use cautioned as sensitization may occur when sulfonamides are readministered. |
|
| Contraindications | Hypersensitivity to any component of this product. Concomitant administration with oral carbonic anhydrase inhibitors is not recommended. |
| Pediatric use | Safety and effectiveness demonstrated in pediatric patients over 3 months of age. |
| Pregnancy | Category C. Teratogenicity shown in rabbits at 37x the human dose but not at 16x. |
| 0.0075% BAK preserved. CAI's exert 70% of waking effect during sleep, prostaglandins 50% and timolol almost none. Bitter taste sometimes encountered. |